Form 4: Dexcom Executive Michael Jon Brown Reports Acquisition of Restricted Stock Units

EVP and Chief Legal Officer of Dexcom, Michael Jon Brown, reports the acquisition of 21,711 restricted stock units.

Summary

• Michael Jon Brown, EVP and Chief Legal Officer of Dexcom Inc., filed a Form 4 on March 11, 2024, reporting a transaction.
• The transaction involved the acquisition of 21,711 shares of Common Stock on March 8, 2024, through a grant of restricted stock units.
• These restricted stock units are exempt from Section 16b-3 and vest in three equal annual installments from the grant date.
• Following the reported transaction, Brown beneficially owns 80,105 shares of Dexcom Inc. Common Stock, including 60,303 unvested restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices and aligns executive interests with company performance.

Positives

• The acquisition of restricted stock units aligns the executive's interests with the long-term performance of the company.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies like Dexcom.

Comparison to Industry Standards

• Executive compensation packages including restricted stock units are a common practice in the medical device industry.
• Companies like Medtronic, Abbott, and Boston Scientific also utilize similar equity-based compensation to incentivize their executives.

Stakeholder Impact

• The granting of restricted stock units can have a positive impact on shareholders by aligning executive interests with the company's long-term success.

Key Dates